Friday, January 13, 2017

NJ Events: Graceful Hope 5th Annual Benefit Dinner

 I am happy to be sharing another event in NJ to raise awareness and funds for ovarian cancer research. This dinner is being held by the Graceful Hope ovarian cancer organization. 




TICKETS ARE CURRENTLY ON SALE for GRACEful Hope's 5th Benefit Dinner to raise funds and awareness for ovarian cancer!

Date: Saturday March 4th, 2017
Location: PISC- Portuguese Instructive Social Club in Elizabeth, NJ

You may purchase them directly on link below.
link: http://gracefulhope.weebly.com/graceful-hopes-5th-benefit.html




Dee
Every Day is a Blessing!

Thursday, January 12, 2017

NJ Area Events : Teal Tea Foundation

As 2017 begins ovarian cancer foundations are planning events to raise awareness and funds for research. The Teal Tea Foundation founded by my friend, Jean Shipos, has a few early 2017 events- all teas, of course.

VALENTINE TEA
FEBRUARY 19, 2017 2:00-4:30PM
Talking Tea Cup
301 West Butler Avenue
Chalfont, PA 18914

$45 admission includes four course tea, entertainment & basket raffles
 Advance online registration required- no tickets at the door- limited seating
ALL SALES FINAL, NO REFUNDS

https://valentinetealtea.eventbrite.com

ST PATRICK TEA

MARCH 19, 2017
Talking Tea Cup
301 West Butler Avenue
Chalfont, PA 18914
 $45 admission includes four course tea, entertainment & basket raffles
Advance online registration required- no tickets at the door- limited seating
ALL SALES FINAL, NO REFUNDS
TICKETS ON SALE TIL MARCH 14, 2017

https://marchafternoontealtea.eventbrite.com

TEAL TEA

May 7, 2017
John Henry’s in Hamilton Township, NJ. 
11th Teal Tea. Theme:  The Sun Will Come Out TEAL-morrow!
Check their website in the future for information. 

  
If there are other organizations that would like me to share their events please e-mail me the information .

Dee
Every Day is a Blessing! Blessed to have so many organizations in NJ raising funds for research. 

Sunday, January 1, 2017

Welcome 2017!

Getting to start a New Year is a real blessing!

If you've read my first posts of the year going back a few years you see that I aspire to things. Some aspirations stay the same from year to year.

I aspire to continue to support other women who are diagnosed with ovarian cancer, to share my story as an ovarian cancer survivor and to promote ovarian cancer research. Some of how I do that might have to change this year because...

I aspire to spend more time with my daughter and her family and my son and his wife. In the Spring my daughter and her family will be living within 4 hours - the closest she has been since she got married nine years ago. I just can't miss the opportunity to spend time with them.

I aspire to build an even better bond with my dog Amber so we can compete at the masters level in agility.

I aspire to travel with my husband and visit at least 2 states I have not visited before. Maine is one of the two. Yes, this was on my 2016 list too. I am not sure what the other state will be.

I aspire to learn a new arts and craft technique. I love to paint so I hope to do that but I'd like to try something new too. That way I can make some more gifts for Christmas next year. 

I aspire to find a way to give back in my community or church.

I wish everyone good health , peace and joy in 2017!


Dee
Every Day is a Blessing!



Friday, December 30, 2016

Nine Years Ago

Has it really been nine years? I never thought when I started this blog on December 30, 2007 that I would be writing it so many years later. But here I am so here I write.

This year was not my most productive - this is my 41st post of the year. That is an average of only 3.4 posts per month.  In July I only wrote one post. In June,  I posted more than three because I couldn't wait to share all the research news I heard at the ASCO annual meeting. Attending that meeting as a survivor/ research advocate is a real privilege and I recommend that if you are a research advocate you apply for a scholarship to attend. Then in November I  tried the WEGOHealth Health Activist Writers Month Challenge but I ended up only writing seven posts. But I enjoyed the prompts that I did respond to.

My most popular posts of 2016 were:

So why did I blog less this year than any of the previous 8 years? I think it is due to an increase in my advocacy work over the past 12 months. I continue to  co-moderate the #gyncsm chat  (2nd Wed. of the month 9pm ET) and post on the communities blog (http://gyncsm.blogspot.com/).  This year we ran a survey so I worked with Christina ( @btrfly12) developing and analyzing the data from that survey to guide our future chats.We draft questions, invite guests, develop resources and promote this monthly chat as well as sharing on Twitter important developments of interest to the gynecologic cancer community on a daily basis. 

As a member of the  Board of the Kaleidoscope of Hope Ovarian Cancer Foundation, which raises funds for ovarian cancer research I oversee the social media (Facebook, Twitter) and the Foundation's website content.  I also volunteer with ASCO, serving as a patient representative on a tumor board and guideline panels.  Then I spent time in October working on a presentation and attending the AZ Patient Summit in Portugal. 

And of course time with family( always my first priority)  cut into the time I would spend writing blog posts. There are times I question whether or not I should continue writing this blog.  But I always come back to my original goal for the blog - to help other women diagnosed with ovarian cancer. Even if I help and support one woman a year I feel I've accomplished something.

So I will keep on writing.

Dee
Every Day is a Blessing! 


Friday, December 23, 2016

Season's Greetings

As I approach the sixth anniversary of writing this blog I want my readers to know how much I appreciate their support and the time you each take to read and comment on my posts. Thank you!

I wish my readers


Dee


Thursday, December 22, 2016

Last Research News of 2016 - Rubraca and FoundationFocus™ CDxBRCA

Another FDA approval for an ovarian cancer treatment happened this week.

"Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test." - FDA (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm)

Rubraca (rucaparib) is a PARP (poly ADP-ribose polymerase)  inhibitor made by Clovis Oncology. The approval is based on two trials. One of the trials is the ARIEL2 trial. In that trial the duration of response was 11.6 months. 

Along with Rubraca, the FDA also approved the  FoundationFocus™ CDxBRCA companion diagnostic to identify those women diagnosed with ovarian cancer who have a BRCA mutation.  This is the first next-generation-sequencing (NGS)-based companion diagnostic approved by the FDA. The test by Foundation Medicine, Inc.  can test for both germline and somatic BRCA mutations in tumor tissue. Germline are inherited mutations and somatic are acquired mutations. 
 
Sources :



Dee
Every Day is a Blessing! 

Saturday, December 17, 2016

Avastin ( Bevacizumab) Approval Expanded for Platinum Sensitive Ovarian Cancer

Earlier this month the FDA approved the expanded use of Avastin (bevacizumab) for platinum sensitive ovarian cancer (OC) . Being platinum sensitive means that a women has a recurrence 6 months or more from her last treatment.

Avastin may be used for:
"Recurrent epithelial ovarian , fallopian tube or primary peritoneal cancer that is
  • platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
  • platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed byAvastin as a single agent (1.6) "
The complete label of use for Avastin / bevacizumab may be found here.

This approval is based on two phase III studies. One study, GOG-213, showed a 5 month longer overall survival for women with platinum sensitive OC when treated with  bevacizumab and chemotherapy versus chemotherapy alone. The other study, OCEANS, showed a median progression free survival of  4 months for those receiving Avastin and chemotherapy versus those receiving placebo and chemotherapy.

Avastin had previously been approved in 2014 for women with platinum resistant ovarian cancer, fallopian tube and primary peritoneal in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.


Dee
Every Day is a Blessing! Happy to see more options for women with platinum sensitive OC. 



Sources
Roche:
http://www.roche.com/media/store/releases/med-cor-2016-12-07.htm

Cure Today:
http://www.curetoday.com/articles/avastin-gets-expanded-fda-approval-for-platinumsensitive-ovarian-cancer 

Genentech:
https://www.gene.com/media/press-releases/14647/2016-12-06/fda-approves-genentechs-avastin-bevacizu